Cevdet KAYA, Abdullah İLKTAÇ, Mustafa GÜNEŞ, Metin ÖZTÜRK, Hüseyin KANBEROĞLU, Muhammet İhsan KARAMAN

The efficacy of trospium chloride in overactive bladder

Amaç: Aşırı aktif mesane sendromu bulunan kadınlarda trospium tedavisinin etkinliği ve bu etkinin ürodinamik bulgular ile ilişkisi araştırıldı. Materyal Metod: Aşırı aktif mesane sendromu bulunan 44 kadın hasta çalışmaya alındı. 8 haftalık trospiyum tedavisinden sonra, hastaların tedavi öncesi ve sonrası OAB-V8 semptom skoru, ürodinamik bulguları karşılaştırıldı. Bulgular: Ortalama OAB-V8 semptom skoru tedavi ile birlikte anlamlı olarak düşük bulundu (11.9+6.3; 24.9+5.1; p

Aşırı aktif mesane sendromu olan kadınlarda trospıum chloride tedavisinin etkinliği

Objective: The efficacy of trospium chloride on the lower urinary tract symptoms and urodynamic parameters in women with OAB were investigated. Material and Methods: 44 consecutive women with OAB were enrolled in this study. Before and after 8 weeks of TC treatment, OAB-V8 scores of the patients related to the current symptoms were collected. Urodynamic studies were performed in 28 patients (63.6%). Primary and outcome variables were OAB symptom score and urodynamic findings. The difference in response to TC according to the lower urinary tract symptoms between the patients with or without proven detrusor overactivity was analyzed. Results: Mean OAB-V8 score of the patients after the treatment with TC was significantly lower than before the treatment (11.9+6.3; 24.9+5.1; p<0.05). After treatment, when compared to the mean OAB-V8 score of patients without DO (14.2+5.3), mean symptom score of those with proven DO (10.3+4.1) was found to be statistically lower (p<0.05). Conclusion: Trospium was much more effective in women with proven DO than without DO to improve symptoms.

PDF

___

1) Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Subcommittee of the International Continence Society. Neurourol Urodyn 2002: 21: 167-78
2) Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int 2001: 87: 760-6
3) Milson I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 6 (Suppl. 11) 2000: S565-73
4) Yoshimura N, de Groat WC. Neural control of lower urinary tract. Int J Urol 1997: 4: 111-25
5) De Groat WC. A neurologic basis for the overactive bladder. Urology suppl. 1997: 50: 36-52
6) Wang P, Luthin GR and Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995: 273: 959-66
7) Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002: 168:1897-1913
8) Wein AJ. Neuromuscular dysfunction of lower urinary tract and its management. In: Walsh PC, Retik AB, Darracot Vaughan jr. E, Wein AJ (eds) Campell’s Urology. Saunders, Philadelphia, 2002: 931-1026
9) Madersbacher H, Rovner E. Trospium chloride: the European experience. Expert Opin Pharmacother 2006: 7(10):1373-80
10) Hofner K, Oelke M, Machtens S, Grunewald T. Trospium chloride an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urol 2001: 19: 336-43
11) Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 1986: 42: 1243-1285
12) Vereecken RL. A critical view on the value of urodynamics in non neurogenic incontinence in women. Int Urogynecol J 2000: 11(3): 188-95
13) Coyne KS, Zyczynski T, Margolis MK, Elinof V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005: 22: 381-94
14) Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic cost of overactive bladder in the United States. Urology 2003: 61: 1123-8
15) Naoki Y, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002: 168: 1897-1913
16) Zinner M, Gittelman M, Haris R, Suuset J, Kanellos A et al. Trospium chloride improves bladder symptoms. A multicenter phase III trial. J Urol 2004:171: 2311-15
17) Halaska M, Ralph G, Wiedeman A, et al. Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2002: 20: 392-9
18) Rudy D, Cline K, Harris R, et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006: 67: 275-280
19) Flisser A, Walmsey K, Blavias JG. Urodynamics classification of patients with symptoms of overactive bladder. J Urol 2003: 169: 529-33
20) Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH. Comparisons of urodynamic characteristics between female patients with overactive bladder and overactive bladder plus stress urinary incontinence. Urology 2004: 64 (5): 945-949
21) Digesu GA, Khullar V, Cardozo L, Stefano S. Overactive bladder symptoms: Do we need urodynamics? Neurourol Urodyn 2003: 22: 105-108
22) Ouslander JG. Management of overactive bladder. N Engl J Med 2004: 350: 786-99
23) Staskin DR, Wein AJ, Andersson KE, et al. Overview consensus statement. Urology 2003: 61: 1128-8
24) Alloussi S, Laval KU, Eckert R, et al. Trospium chloride in patients with motor urge symptoms: A double blind, randomised, multicentre, placebo controlled study. J Drug Asses 1999: 2: 27-39